VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
DCGO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
DCGODocGo Inc.
$0.52$51M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. DCGO
  4. Financial Ratios

DocGo Inc. (DCGO) Financial Ratios

Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE -82.7%. (2019–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

DCGO Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Market Cap$51M$87M$464M$590M$728M$887M$1.0B—
Enterprise Value$29M$65M$432M$578M$591M$728M$999M—
P/E Ratio →-0.28—23.5686.1320.7937.40——
P/S Ratio0.160.270.750.951.652.7810.81—
P/B Ratio0.410.691.471.932.613.9115.19—
P/FCF1.893.227.19—31.15———
P/OCF1.482.526.60—25.22———

P/E links to full P/E history page with 30-year chart

DCGO EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
EV / Revenue—0.200.700.931.342.2810.61—
EV / EBITDA——9.6918.3418.2331.83——
EV / EBIT——14.5538.3727.0535.41——
EV / FCF—2.416.70—25.27———

DCGO Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Gross Margin30.7%30.7%34.6%31.3%35.1%34.4%33.3%27.3%
Operating Margin-27.7%-27.7%4.7%2.4%5.0%4.8%-15.7%-43.0%
Net Profit Margin-56.6%-56.6%3.2%1.1%7.9%7.4%-15.3%-41.8%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
ROE-82.7%-82.7%6.4%2.3%13.7%16.2%-19.6%-25.5%
ROA-54.2%-54.2%4.2%1.6%9.8%11.6%-14.3%-20.0%
ROIC-34.5%-34.5%7.5%5.2%15.6%19.8%-23.2%-33.0%
ROCE-36.9%-36.9%8.8%4.9%8.0%9.4%-17.6%-22.8%

DCGO Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Debt / Equity0.230.230.180.150.070.070.210.20
Debt / EBITDA——1.281.480.610.72——
Net Debt / Equity—-0.17-0.10-0.04-0.49-0.70-0.28-0.41
Net Debt / EBITDA——-0.72-0.41-4.24-6.95——
Debt / FCF—-0.81-0.50—-5.88———
Interest Coverage-87.92-87.9213.70——26.94-72.12—

Net cash position: cash ($51M) exceeds total debt ($29M)

DCGO Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Current Ratio2.262.262.501.992.714.422.496.08
Quick Ratio2.262.262.501.992.664.422.496.08
Cash Ratio0.760.760.730.351.573.031.384.91
Asset Turnover—1.481.351.271.121.030.940.48
Inventory Turnover————63.79———
Days Sales Outstanding—105.23124.85153.2385.3489.7796.4276.80

DCGO Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Dividend Yield——100.0%—————
Payout Ratio——6474653.6%—————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Earnings Yield——4.2%1.2%4.8%2.7%——
FCF Yield53.0%31.1%13.9%—3.2%———
Buyback Yield21.2%12.4%3.0%0.0%0.5%0.1%0.0%—
Total Shareholder Yield21.2%12.4%100.0%0.0%0.5%0.1%0.0%—
Shares Outstanding—$99M$109M$106M$103M$95M$100M$100M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Municipal contract concentration risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Market Pricing Reflects Distressed Outlook

Based on reported figures, DocGo's P/S ratio of 0.15 suggests the market is pricing the company as a distressed asset rather than a growth-oriented healthcare provider, reflecting deep skepticism regarding the sustainability of its current revenue base following the expiration of pandemic-era municipal contracts.

The extremely low P/S multiple relative to broader healthcare services peers indicates that investors are heavily discounting the company's future earnings potential. This valuation appears to reflect a market consensus that the current revenue contraction is structural rather than cyclical, necessitating a significant re-rating of the business model.

Capital Efficiency Deteriorating Amid Losses

According to recent financial statements, DocGo's ROIC has plummeted to -13.5% in 2026Q1, signaling a rapid decay in the company's ability to generate returns on invested capital as operational losses continue to erode the asset base and shareholder equity.

The consistent negative trend in ROIC over the last ten quarters suggests that the company's capital allocation strategy has failed to create value. Investors should monitor whether management can pivot toward higher-margin service lines, as the current trajectory indicates that capital is being consumed rather than compounded.

Working Capital Cycles Remain Strained

As reported in financial statements, DocGo's DSO has remained elevated at 111 days in 2026Q1, highlighting significant friction in cash collection cycles that likely stems from the company's heavy reliance on government-linked contracts and complex municipal billing environments.

The inability to meaningfully reduce DSO suggests that the company lacks leverage over its primary government customers, leading to persistent liquidity pressure. This inefficiency in working capital management forces the company to rely on external financing or cash reserves to bridge the gap between service delivery and payment.

Liquidity Buffer Facing Persistent Erosion

Based on DocGo's reported figures, the current ratio has tightened from 2.59 in 2025Q3 to 1.79 in 2026Q1, indicating that the company's ability to cover short-term obligations is diminishing as cash reserves are depleted to fund ongoing operational losses and working capital requirements.

While a current ratio of 1.79 remains technically above parity, the rapid downward trend warrants caution regarding the company's long-term solvency. The reliance on cash to fund operations during a period of revenue contraction suggests that the liquidity position may become increasingly vulnerable if contract renewals do not materialize.

Misapplication of Tech-Enabled Valuation Multiples

Investors frequently misapply software-as-a-service valuation multiples to DocGo, which obscures the reality that the company operates a labor-intensive, logistics-heavy model with structurally lower margins that cannot support the premium pricing typically afforded to high-growth, scalable technology platforms.

By ignoring the high variable costs associated with clinical labor and fleet maintenance, analysts may overestimate the company's potential for margin expansion. A more appropriate framework would involve benchmarking against industrial services or traditional medical transportation providers, which would likely lead to a more conservative assessment of the company's long-term earning power.

Download Financial Ratios Data

Includes 30+ ratios · 7 years · Updated daily

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

DCGO — Frequently Asked Questions

Quick answers to the most common questions about buying DCGO stock.

What is DocGo Inc.'s P/E ratio?

DocGo Inc.'s current P/E ratio is -0.3x. The historical average is 42.0x.

What is DocGo Inc.'s ROE?

DocGo Inc.'s return on equity (ROE) is -82.7%. The historical average is -12.7%.

Is DCGO stock overvalued?

Based on historical data, DocGo Inc. is trading at a P/E of -0.3x. Compare with industry peers and growth rates for a complete picture.

What are DocGo Inc.'s profit margins?

DocGo Inc. has 30.7% gross margin and -27.7% operating margin.